These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31245460)

  • 1. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells.
    Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
    Regen Ther; 2015 Dec; 2():57-69. PubMed ID: 31245460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of allogeneic human somatic stem cells.
    Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
    Regen Ther; 2015 Dec; 2():70-80. PubMed ID: 31245461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of autologous human induced pluripotent stem(-like) cells.
    Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
    Regen Ther; 2015 Dec; 2():81-94. PubMed ID: 31245462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from processing of allogeneic human induced pluripotent stem(-Like) cells.
    Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
    Regen Ther; 2015 Dec; 2():95-108. PubMed ID: 31245463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of human embryonic stem cells.
    Hayakawa T; Aoi T; Umezawa A; Ozawa K; Sato Y; Sawa Y; Matsuyama A; Yamanaka S; Yamato M
    Regen Ther; 2015 Dec; 2():109-122. PubMed ID: 31245464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
    Okada K; Koike K; Sawa Y
    Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumorigenicity assessment of human cell-processed therapeutic products.
    Yasuda S; Sato Y
    Biologicals; 2015 Sep; 43(5):416-21. PubMed ID: 26071041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [On improvement of the mechanism for establishing and changing indicators of quality and food safety in the regulatory and legal acts of the Eurasian Economical Union].
    Arnautov OV
    Vopr Pitan; 2016; 85(1):110-6. PubMed ID: 27228709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Science of evaluating the characteristics, quality and safety of biotechnological products: RDNA-derived products, cell culture technology-derived products, gene therapy products, cellular therapy products, and transgenic animal-derived protein products and cellular products].
    Hayakawa T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1999; (117):1-38. PubMed ID: 10859934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Regulatory Science in Practice (Pharmaceuticals and Medical Devices Agency)].
    Hojo T
    Yakugaku Zasshi; 2017; 137(4):439-442. PubMed ID: 28381721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reconsideration of the admission and discharge criteria of tuberculosis patients in Japan].
    Masuyama H; Igari H
    Kekkaku; 2013 Mar; 88(3):373-85. PubMed ID: 23672177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of guidance for the approval process of brand-new medical products and regenerative medicine products].
    Niimi S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2015; (133):1-7. PubMed ID: 26821464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacopoeia as quality codex for the manufacturers.
    Soldi A
    Ann Ist Super Sanita; 1975; 11(3-4):269-80. PubMed ID: 1234728
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.